Baseline and changes in inflammatory parameters for patients with EGFR ‐mutated NSCLC treated with afatinib
Sign Up to like & getrecommendations! Published in 2025 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.15338
Abstract: This study investigated the relationship between inflammatory biomarkers (lymphocyte ratio [NLR], monocyte‐to‐lymphocyte ratio [MLR], and platelet‐to‐lymphocyte ratio [PLR]) and the treatment outcomes of patients with non‐small cell lung cancer (NSCLC) treated with afatinib. read more here.
Keywords: inflammatory parameters; treated afatinib; baseline changes; changes inflammatory ... See more keywords
Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression
Sign Up to like & getrecommendations! Published in 2017 at "PLoS ONE"
DOI: 10.1371/journal.pone.0182885
Abstract: Purpose To determine survival in afatinib-treated patients after treatment with first-generation EGFR tyrosine kinase inhibitors (TKIs) and to study resistance mechanisms in afatinib-resistant tumors. Methods Characteristics and survival of patients treated with afatinib after resistance… read more here.
Keywords: egfr; afatinib; patients treated; treated afatinib ... See more keywords